Spain Reviewing Trial to Treat COVID-19 Pneumonia With Myeloma Therapy Aplidin
Madrid-based PharmaMar has submitted the protocol for a Phase 2 trial to the Spanish Medicines and Healthcare Products Agency (AEMPS) to test its multiple…
Aplidin Prolongs Survival and Time to Disease Progression in Heavily Treated Multiple Myeloma Patients, Phase 3 Trial Shows
Aplidin (plitidepsin) in combination with dexamethasone significantly prolonged the survival and time to disease progression or death in heavily treated patients with…
Aplidin Approved in Australia for Relapsed or Refractory Multiple Myeloma
Treatment with Aplidin (plitidepsin) in combination with dexamethasone was approved in Australia for multiple myeloma patients who have failed or are resistant to…
Aplidin-Dexamethasone Combo Improves Survival in Advanced Multiple Myeloma Patients, Phase 3 Trial Reports
Combining Aplidin (plitidepsin) with dexamethasone significantly extends their survival in heavily pretreated multiple myeloma patients compared to dexamethasone alone, data from a Phase 3 trial…
PharmaMar Launches Aplidin Quadruple Combo Trial in Myeloma
PharmaMar is launching a clinical trial to explore its investigational therapy Aplidin (plitidepsin) in a quadruple combination treatment for multiple myeloma. The four compounds involved…
Switzerland Grants PharmaMar’s Aplidin Orphan Drug Status to Treat Multiple Myeloma
Switzerland’s Agency for Therapeutic Products (Swissmedic) has awarded PharmaMar’s Aplidin orphan drug status to treat patients with multiple myeloma, following a similar designation by the U.S. Food…
PharmaMar Seeks EU Approval for Aplidin to Treat Multiple Myeloma
PharmaMar has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for the use of Aplidin (plitidepsin) in combination with Decadron (dexamethasone, an…
